Key hallmark of ALS is successfully reversed in laboratory 9 August 2021 | By Anna Begley (Drug Target Review) Scientists demonstrated how to reverse the incorrect localisation of three RNA-binding proteins in ALS, potentially leading to treatments.
Researchers reveal how microbiome bacteria adapt through transmission 9 August 2021 | By Anna Begley (Drug Target Review) Scientists have used genetic sequencing to demonstrate how the transmission of gut bacteria influences its evolution and functions, which could effect human health.
Licensed drug may reduce COVID-19 infection by 70 percent 6 August 2021 | By Anna Begley (Drug Target Review) Fenofibrate and its active form, fenofibric acid, have been shown to significantly reduce COVID-19 infection in human cells.
Artificial intelligence may reveal how microbiome affects vaccine response 6 August 2021 | By Anna Begley (Drug Target Review) Researchers have been using artificial intelligence to study how the microbiome interacts with the human system to improve vaccine response.
Therapeutic target for aggressive cancers discovered through CRISPR 5 August 2021 | By Anna Begley (Drug Target Review) The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
Prize winner uncovers how microbiome can combat neurodegeneration 5 August 2021 | By Anna Begley (Drug Target Review) Eran Blacher has won the NOSTER & Science Microbiome Prize for discovering the link between the microbiome and neurodegenerative diseases.
CRISPR-Cas9 used to prevent Fuchs’ corneal dystrophy in mice 4 August 2021 | By Anna Begley (Drug Target Review) Scientists have shown that start codon disruption with CRISPR-Cas9 gene editing can prevent Fuchs’ corneal dystrophy in mouse models.
Novel database could accelerate drug repurposing for various diseases 4 August 2021 | By Anna Begley (Drug Target Review) NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
Mitochondria repair in mice may provide answers on Parkinson’s disease 4 August 2021 | By Anna Begley (Drug Target Review) Researchers used an experimental small molecule that helped restore the removal of damaged mitochondria from brain cells in a mouse model of Parkinson's.
Synthetic “switch” is a pivotal step for smart insulin therapy 3 August 2021 | By Anna Begley (Drug Target Review) A novel synthetic “switch” has been developed that could hold the key to revolutionary smart insulin therapy for diabetic patients.
Masitinib found to be an effective COVID-19 treatment in mouse model 3 August 2021 | By Anna Begley (Drug Target Review) Scientists from the University of Chicago discovered that the drug masitinib inhibits the replication of SARS-CoV-2 in mice.
Sunlight shown to trigger DNA mutation that causes melanoma 3 August 2021 | By Anna Begley (Drug Target Review) New research found mutations that cause melanoma result from a chemical conversion in DNA fuelled by sunlight, undermining previous theories.
Thalamus revealed as key area to target for certain brain disorders 2 August 2021 | By Anna Begley (Drug Target Review) Research shows that cells gather more data inside the thalamus than once believed, potentially changing medicines for brain disorders.
Enzyme found to be an “Achilles’ heel” in ovarian cancers 2 August 2021 | By Anna Begley (Drug Target Review) Scientists have uncovered the crucial role of the enzyme NMNAT-2 in ovarian cancers, as well as other biomarkers that could lead to treatments.
Genes behind antibiotic activity in bacteria uncovered by metabologenomics 2 August 2021 | By Anna Begley (Drug Target Review) Researchers have used comparative metabologenomics to uncover what may be “silencing” bacteria to produce desirable compounds.
